Adjuvant CDK Inhibitors for EBC

CE / CME

Integrating Adjuvant CDK4/6 Inhibitors Into Care of Patients With HR-Positive/HER2-Negative Early-Stage Breast Cancer

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: May 01, 2024

Expiration: April 30, 2025

Activity

Progress
1 2
Course Completed

Introduction

In this case-based module, Tanya Gupta, MD, discusses key data and expert guidance on incorporating adjuvant CDK4/6 inhibitors into the treatment of patients with hormone receptor (HR)–positive/HER2-negative early-stage breast cancer (EBC), including patient selection, adverse event (AE) management, and adherence considerations.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Two questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with breast cancer do you provide care for in a typical month?

A 45-year-old premenopausal woman with underlying inflammatory bowel disease underwent lumpectomy and sentinel node biopsy, with surgical pathology demonstrating a 3.5-cm invasive ductal carcinoma, grade 3, with 2 of 3 sampled nodes positive. Her biomarkers are estrogen receptor 80%, progesterone receptor 30%, and HER2 negative (immunohistochemistry [IHC] 0). Germline BRCA testing is negative. She receives adjuvant chemotherapy with dose‑dense AC-T (doxorubicin and cyclophosphamide followed by paclitaxel) followed by radiation therapy.

In addition to ovarian suppression, which of the following adjuvant therapies would you recommend for this patient?

A 62-year-old postmenopausal woman initiates adjuvant therapy with an AI plus abemaciclib at 150 mg twice daily to treat her high-risk HR-positive/HER2-negative breast cancer. The routine complete blood count (CBC) performed 4 weeks later finds that her absolute neutrophil count (ANC) is 800/mm3.

Which of the following management strategies would you recommend for this patient with grade 3 neutropenia?